The study is testing a new drug called NKT3447 for adults with advanced or metastatic solid tumors. These are serious cancers that have spread or cannot be removed by surgery. The study is in two parts. The first part, called Dose Escalation, is to find a safe dose of NKT3447. The second part, called Dose Expansion, will test the drug on more people with a certain type of ovarian cancer to see if it works.
Metastatic means cancer has spread to other parts of the body. Pharmacokinetics (PK) is how the body processes a drug. CCNE1 is a specific gene that can be linked to cancer growth.
- The study involves regular check-ups and tests to monitor safety and how the drug affects the body.
- Participants need to have specific types of cancer that have not responded to usual treatments.
- People with certain health conditions, like active infections or recent surgeries, cannot join.
This study could help find new treatments for hard-to-treat cancers, but participating involves some risks and commitment to regular medical visits.
How understandable was the trial content above?
Hard to understand
Easy to understand